TP53mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer

TP53status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

(2014) Hans P. Eikesdal et al.   ACTA ONCOLOGICA

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

(2012) James G. Jackson et al.   CANCER CELL

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

(2011) Stefan Glück et al.   BREAST CANCER RESEARCH AND TREATMENT

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

(2011) Hervé Bonnefoi et al.   LANCET ONCOLOGY

The role of mutant p53 in human cancer

(2010) Amanda M Goh et al.   JOURNAL OF PATHOLOGY

Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers

(2010) J. Lehmann-Che et al.   ONCOLOGIST

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Mutant p53 Gain-of-Function in Cancer

(2009) M. Oren et al.   Cold Spring Harbor Perspectives in Biology

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors

(2008) Mariana Varna et al.   INTERNATIONAL JOURNAL OF CANCER

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY